Biotechnology company Baebies has secured de novo clearance from the US Food and Drug Administration (FDA) for the use of its newborn screening platform SEEKER in diagnosis of lysosomal storage diseases (LSDs).

The new device is designed to quantitatively measure the activity of lysosomal enzymes α-L-iduronidase (IDUA), α-D-glucosidase (GAA), β-glucocerebrosidase (GBA) and α-D-galactosidase A (GLA) in dried blood spot samples of newborns.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The detection of a decrease in the activity of these lysosomal enzymes indicates the presence of LSDs such as Mucopolysaccharidosis Type I (MPS I), Pompe, Gaucher or Fabry.

Baebies president and co-founder Vamsee Pamula said: "Although these LSDs have FDA approved therapies, this is a significant milestone for the LSD community, as SEEKER is the first FDA cleared product for LSD testing.

"FDA's clearance of SEEKER resulted from a thorough and rigorous review.

"We look forward to providing SEEKER kits to implement safe, effective, easy and reliable screening for LSDs. SEEKER is the only FDA authorised test on the market."

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Initiated to ensure the screening of all babies for certain serious conditions at birth, the Newborn screening health programme currently includes more than 30 metabolic and genetic diseases.

"This is a significant milestone for the LSD community, as SEEKER is the first FDA cleared product for LSD testing."

The Pompe disease and MPS I were recently included in the Recommended Uniform Screening Panel (RUSP), enabling early detection of LSDs via newborn screening.

It is expected that the FDA clearance will allow to reduce the validation effort with the implementation of the cost effective screening.

Baebies develops new technologies and tests for advance newborn screening and pediatric testing.


Image: SEEKER Instrument. Photo: courtesy of Baebies.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact